Sep 06, 2023 / 07:00PM GMT
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst
All right. Good afternoon, everyone. I'm Larry Biegelsen, the medical device analyst at Wells Fargo. It's my pleasure to host this session with the management from the CooperCompanies.
With us, we have Al White, President and CEO; Kim Duncan, Vice President of IR and Risk Management. In terms of format, it's going to be a fireside chat. If you have a question, please raise your hand. We'll come around with the mic. So Al and Kim, thanks so much for being here.
Albert G. White - CooperCompanies - President, CEO & Non-Independent Director
Yes. Thanks, Larry.
Questions and Answers:
Lawrence H. Biegelsen - Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research AnalystSo Al, let's start with a recap of the Q3 results. Very strong organic growth of 12%, but EPS only beat consensus, I think, by $0.01 despite the top line beat of about $30 million. So talk